EGFR and non-small cell lung carcinoma: Afatinib is a second-generation EGFR-TKI, a combined post-hoc analysis of LUX-Lung 2/3/6 showed that afatinib was active in advanced NSCLC patients that harbored certain uncommon EGFR mutations.